Antigestagene

J F van Uem, G D Hodgen
Geburtshilfe und Frauenheilkunde · 1988 · vol. 48(12) , pp. 829–834 · doi:10.1055/s-2008-1026636 · PMID:3069562 · W4253692283
review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-09 ⓘ

This paper discusses novel 19-norprogestin derivatives of the RU 486 type, exploring their potential therapeutic applications in fertility control, cancer, endometriosis, and labor induction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Recently potent 19-norprogestin derivatives of the RU 486-type were developed. Acting at the receptor level, these steroids are considered a major breakthrough in steroid endocrinology. Clinical studies indicate their potential use in fertility control. Besides biochemical, pharmacological and clinical aspects of the antiprogestins, the ultimate role in the therapeutic management of certain endometrial and breast cancers, endometriosis as well as induction of labour at term are discussed.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral, Synthetic Estrenes Progestins Animals Contraceptives, Oral, Synthetic Estrenes Female Humans Mifepristone Pregnancy Progestins Structure-Activity Relationship

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:20.810540+00:00
License: CC0 · commercial use OK